US EditionPublished • loading... • Updated
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
- CStone has received FDA clearance to start a global Phase II clinical trial for its novel trispecific antibody, CS2009, according to Dr. Jason Yang, CEO of CStone.
- The FDA reviewed Phase I data on safety and antitumor activity and agreed on key Phase II study design elements, including dose optimization.
- CS2009 targets PD-1, VEGFA, and CTLA-4 to deliver multidimensional antitumor effects through synergistic actions.
- The ongoing Phase II trial is multi-cohort, testing CS2009 as monotherapy and in combination, enrolling patients in Australia and China, with IND clearance in the U.S..
Insights by Ground AI
52 Articles
52 Articles
The Berkshire Eagle+51 Reposted by 51 other sources
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global…
Coverage Details
Total News Sources52
Leaning Left6Leaning Right7Center21Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 18%
C 62%
R 20%
Factuality
To view factuality data please Upgrade to Premium
